- Receptor-based Targeting of Therapeutics
Neelesh Kumar Mehra et al, 2013, Therapeutic Delivery CrossRef - DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma
Anne Yagolovich et al, 2022, International Journal of Molecular Sciences CrossRef - Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy
Agathe Dubuisson et al, 2017, Antibodies CrossRef - MRI-guided liposomes for targeted tandem chemotherapy and therapeutic response prediction
Lili Ren et al, 2016, Acta Biomaterialia CrossRef - Differentially cross-linkable core–shell nanofibers for tunable delivery of anticancer drugs: synthesis, characterization and their anticancer efficacy
S. Uday Kumar et al, 2014, RSC Adv. CrossRef - The fibronectin III-1 domain activates a PI3-Kinase/Akt signaling pathway leading to αvβ5 integrin activation and TRAIL resistance in human lung cancer cells
Christina Cho et al, 2016, BMC Cancer CrossRef - The Effects of the Carrier and Ligand Spatial Conformation on RNA Nanodrug Cell Delivery
Zhuang Zhang et al, 2024, Analytical Chemistry CrossRef - RGD and NGR modified TRAIL protein exhibited potent anti-metastasis effects on TRAIL-insensitive cancer cells in vitro and in vivo
Xiaofei Wang et al, 2017, Amino Acids CrossRef - FERM domain‐containing protein FRMD5 regulates cell motility via binding to integrin β5 subunit and ROCK1
Jinxia Hu et al, 2014, FEBS Letters CrossRef - AZD9291 Resistance Reversal Activity of a pH‐Sensitive Nanocarrier Dual‐Loaded with Chloroquine and FGFR1 Inhibitor in NSCLC
Yu Gu et al, 2021, Advanced Science CrossRef - Apoptosis and apoptotic body: disease message and therapeutic target potentials
Xuebo Xu et al, 2019, Bioscience Reports CrossRef